Actively Recruiting
Evaluating Growth, Tolerance, and Biomarkers in Healthy Infants Receiving Probiotic and Placebo Dietary Supplements A Randomized, Double-Blind Nutritional Study
Led by Société des Produits Nestlé (SPN) · Updated on 2026-09-14
327
Participants Needed
2
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating growth, tolerance, and functional biomarkers in healthy infants aged 14 to 28 days receiving dietary supplements over an 8-week period. This double-blind, randomized, placebo-controlled nutritional study includes approximately 327 healthy term infants of all feeding types. The primary goal is to compare weight gain velocity among infants given single probiotic, multi-probiotic, or placebo supplements, with secondary outcomes exploring gastrointestinal health, microbiome composition, and safety. Participants are randomly assigned to one of three groups receiving either a single probiotic supplement, a multi-probiotic supplement, or a placebo, all administered once daily in powdered form. The intervention lasts for 8 weeks followed by a 4-week follow-up, totaling about 3 months of participation. The study monitors infants from baseline until 2.5 months of age to assess growth and tolerance. During the study, infants have scheduled assessments at baseline, 1.5 months, and 2.5 months, which include measurements of weight, length, head circumference, and gastrointestinal symptoms through questionnaires and diaries. Stool samples are collected to evaluate microbiome and metabolic markers, and safety is monitored by physical exams, vital signs, and adverse event reporting throughout the study and follow-up period.
CONDITIONS
Brief Title
Growth, Tolerance, and Functional Biomarkers in Healthy Infants Receiving Dietary Supplements
Research Team
J
Joyce Li
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here